Aller au contenu principal
← Tous les financements vérifiés
Tier AUS

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

National Institutes of Health

Connectez-vous et complétez votre Funding Passport pour voir si vous êtes admissible — un verdict transparent, fondé sur des règles, pas une boîte noire.

Se connecter

À propos de cette possibilité

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Documents requis

La source officielle n'indique pas de documents précis ici — vérifiez les exigences avant de postuler.

Source et traçabilité de vérification

Première collecte
20 novembre 2026
Dernière vérification
20 novembre 2026
Empreinte du contenu
595c18a936f6d861…